Q-omics provides the consensus-scored CRYAA profile across patient tissues and cancer cell-line models. CRYAA expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CRYAA is differentially expressed in 6, with the highest sampling consensus in KIRP. Additionally, CRYAA RNA expression shows 5,384 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KIRP, and TGCT as cancer lineages where CRYAA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRYAA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRYAA survival associations across molecular data types. CRYAA RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRYAA RNA expression–survival associations across cancer types. High CRYAA expression shows unfavorable associations in KICH and UVM, but favorable associations in KIRC, LIHC, OV and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .009). Together, the overview and detailed table identify KIRC as the clearest survival context for CRYAA RNA expression.
This table summarizes CRYAA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for CRYAA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRYAA shows lower tumor expression in KIRP, KICH, KIRC, LIHC and LUSC and higher tumor expression in HNSC. The KIRP box plot shows higher CRYAA RNA expression in normal versus tumor tissue (log2 FC = −0.755, t-test p < 0.001).
This table shows molecular features associated with CRYAA in patient tissues and cancer cell lines. In patient samples, CRYAA shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CRYAA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and SKIN.
